CL2018003109A1 - Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos. - Google Patents

Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos.

Info

Publication number
CL2018003109A1
CL2018003109A1 CL2018003109A CL2018003109A CL2018003109A1 CL 2018003109 A1 CL2018003109 A1 CL 2018003109A1 CL 2018003109 A CL2018003109 A CL 2018003109A CL 2018003109 A CL2018003109 A CL 2018003109A CL 2018003109 A1 CL2018003109 A1 CL 2018003109A1
Authority
CL
Chile
Prior art keywords
benzoimidazol
hydroxy
acrylamide
diethylamino
butyl
Prior art date
Application number
CL2018003109A
Other languages
English (en)
Inventor
David Duncan
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of CL2018003109A1 publication Critical patent/CL2018003109A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCRIBEN POLIMORFOS DE FORMAS CRISTALINAS DEL 3-[2-BUTIL-1-(2-DIETILAMINO-ETIL)-1H-BENZOIMIDAZOL-5-IL]-N-HIDROXI-ACRILAMIDA. TAMBIÉN SE PRESENTAN COMPOSICIONES FARMACÉUTICAS Y LOS USOS DE LAS MISMAS, FORMAS COMPUESTAS Y COMPOSICIONES, PARA EL TRATAMIENTO DE ENFERMEDADES Y AFECCIONES.
CL2018003109A 2016-05-02 2018-10-31 Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos. CL2018003109A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662330673P 2016-05-02 2016-05-02

Publications (1)

Publication Number Publication Date
CL2018003109A1 true CL2018003109A1 (es) 2019-04-26

Family

ID=60203321

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003109A CL2018003109A1 (es) 2016-05-02 2018-10-31 Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos.

Country Status (20)

Country Link
US (2) US10626092B2 (es)
EP (2) EP3939966A1 (es)
JP (1) JP2019514905A (es)
KR (1) KR20190005904A (es)
CN (1) CN109414425A (es)
AR (1) AR108257A1 (es)
AU (1) AU2017261218A1 (es)
BR (1) BR112018072439A2 (es)
CA (1) CA3022011A1 (es)
CL (1) CL2018003109A1 (es)
CO (1) CO2018012941A2 (es)
EA (1) EA201892341A1 (es)
ES (1) ES2886495T3 (es)
IL (1) IL262578A (es)
MA (1) MA44880A (es)
MX (1) MX382095B (es)
PH (1) PH12018502296B1 (es)
SG (1) SG11201809471UA (es)
TW (1) TW201741286A (es)
WO (1) WO2017192451A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110291071B (zh) * 2017-02-28 2022-04-26 苏州科睿思制药有限公司 Sb-939的盐的晶型及其制备方法和用途
WO2019126282A1 (en) 2017-12-19 2019-06-27 Assia Chemical Industries Ltd. Crystalline polymorphs of pracinostat and pracinostat salts
WO2019149262A1 (zh) * 2018-02-05 2019-08-08 苏州科睿思制药有限公司 Sb-939的晶型及其制备方法和用途
WO2021217180A1 (en) * 2020-04-22 2021-10-28 Johnson Matthey Public Limited Company Novel forms of pracinostat dihydrochloride

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2291749A1 (fr) 1974-11-20 1976-06-18 Delalande Sa Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique
CA2135173A1 (en) 1992-05-20 1993-11-25 Bruce E. Witzel Ester derivatives of 4-aza-steroids
SE9804212D0 (sv) 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
IL144214A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
WO2001000207A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
AU5636900A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
DK1202724T3 (da) 1999-07-16 2004-01-26 Warner Lambert Co Fremgangsmåde til behandling af kronisk smerte under anvendelse af mek-inhibitorer
AU6068600A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
GB9919558D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
CA2391952C (en) 1999-11-23 2012-01-31 Methylgene Inc. Inhibitors of histone deacetylase
EP1162196A4 (en) 1999-12-27 2003-04-16 Japan Tobacco Inc COMPOUNDS WITH JOINED CYCLES AND THEIR USE AS MEDICAMENTS
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CA2428191A1 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003066889A2 (en) 2002-02-07 2003-08-14 Axys Pharmaceuticals, Inc. Assay for acytyltransferase or deacetylase activity
WO2003077855A2 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
TWI343377B (en) 2002-03-13 2011-06-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
CA2484261A1 (en) 2002-04-16 2003-10-23 Teijin Limited Piperidine derivatives having ccr3 antagonism
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US7151096B2 (en) 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
KR101127201B1 (ko) 2003-09-22 2012-04-12 에스*바이오 피티이 리미티드 벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용
WO2005066151A2 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
CA2540459C (en) * 2005-09-08 2014-02-18 S*Bio Pte Ltd Benzimidazole compounds and uses in treating proliferative disorders
DK1937650T3 (da) * 2005-09-08 2011-10-03 S Bio Pte Ltd Heterocykliske forbindelser
ES2703592T3 (es) * 2007-03-07 2019-03-11 Mei Pharma Inc Combinación de agente anticancerígeno de bencimidazol y un segundo agente anticancerígeno
SMT202000168T1 (it) 2012-10-30 2020-05-08 Mei Pharma Inc Terapie di combinazione per il trattamento dei tumori chemioresistenti

Also Published As

Publication number Publication date
PH12018502296A1 (en) 2019-07-08
CN109414425A (zh) 2019-03-01
CO2018012941A2 (es) 2018-12-28
AR108257A1 (es) 2018-08-01
US20200317621A1 (en) 2020-10-08
MA44880A (fr) 2021-03-17
TW201741286A (zh) 2017-12-01
CA3022011A1 (en) 2017-11-09
JP2019514905A (ja) 2019-06-06
US10626092B2 (en) 2020-04-21
EA201892341A1 (ru) 2019-05-31
SG11201809471UA (en) 2018-11-29
EP3452035B1 (en) 2021-07-07
EP3939966A1 (en) 2022-01-19
PH12018502296B1 (en) 2022-04-06
MX382095B (es) 2025-03-13
KR20190005904A (ko) 2019-01-16
BR112018072439A2 (pt) 2019-02-19
WO2017192451A1 (en) 2017-11-09
MX2018013349A (es) 2019-02-20
ES2886495T3 (es) 2021-12-20
US20190152923A1 (en) 2019-05-23
IL262578A (en) 2018-12-31
EP3452035A1 (en) 2019-03-13
EP3452035A4 (en) 2019-09-25
AU2017261218A1 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2019013016A2 (es) Inhibidores pirazólicos de magl
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2018001569A1 (es) Compuestos heteroaromáticos como inhibidores de btk
CO2019004945A2 (es) Inhibidores de la magl
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2019005059A2 (es) Inhibidores de magl
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CO2019005038A2 (es) Inhibidores de magl
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CL2019002583A1 (es) Inhibidores duales de magl y faah.
CL2018001085A1 (es) Derivados de indolin-2-ona
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
DOP2016000161A (es) Ureas asimétricas p- sustituidas y usos médicos de las mismas.
CO2018012941A2 (es) Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2018004868A (es) Derivados de la pirrolidina.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades